Subchondral Bone Injections for the Treatment of Knee Osteoarthritis.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 42246016.
- Also identified by DOI 10.22038/ABJS.2025.88678.4020 and PMC identifier 13231255.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The existing literature on whether subchondral bone injections in knee osteoarthritis is advisable for relieving patient pain is minimal and the level of evidence is low. A recent case series (2023) analyzed 30 individuals with knee OA (Kellgren-Lawrence 2-3). It showed that combined intraarticular and subchondral BMAC (bone marrow aspirate concentrate injections) provided clinical and imaging benefits up to 24 months for the treatment of symptomatic knee OA, with a low failure rate, and a significant reduction of bone marrow edema. Besides, VAS (visual analog scale) pain worsened at the final follow-up, although remained lower compared to the baseline value. Although some studies mention that subchondral bone injections can relieve pain in mild/moderate knee OA, it does not seem reasonable to advise it until better-designed research can confirm the preliminary studies discussed in this article.